Table 1 Patient and tumor characteristics by study cohort
Characteristic | Total patients (n = 27) | PIK3CA/AKT cohort (n = 18) | PTEN cohort (n = 9) |
|---|---|---|---|
Age | |||
 Mean (range) | 52 (30–73) | 54 (33–73) | 48 (30–68) |
Race | |||
 Caucasian | 24 (89%) | 16 (89%) | 8 (89%) |
 African-American | 3 (11%) | 2 (11%) | 1 (11%) |
ECOG performance status | |||
 0 | 19 (70%) | 13 (72%) | 6 (67%) |
 1 | 8 (30%) | 5 (28%) | 3 (33%) |
Subtype | |||
 HR+ | 15 (56%) | 12 (67%) | 3 (33%) |
 TNBC | 9 (33%) | 4 (22%) | 5 (56%) |
 HER+ | 3 (11%) | 2 (11%) | 1 (11%) |
Molecular subtype | |||
 PIK3CA mutant | 13 (48%) | 13 (72%) | – |
 AKT1 mutant | 4 (15%) | 4 (22%) | – |
 PIK3CA mutant and PTEN loss | 1 (4%) | 1 (6%) | – |
 PTEN loss | 9 (33%) | – | 9 (100%) |
Number of prior therapies | |||
 2 | 2 (7%) | 1 (5%) | 1 (11%) |
 3 | 3 (11%) | 1 (5%) | 2 (22%) |
 ≥ 4 | 22 (82%) | 16 (90%) | 6 (67%) |